Tenax Therapeutics, Inc.
NASDAQ:TENXBiotechnology
+$0.10 today
- Market cap
- $50.66M
- Beta
- 0.97
- P/E (TTM)
- -9.4
- EPS (TTM)
- -$1.28
Volume 0.70M
Average 0.62M
TENX EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
Tenax Therapeutics, Inc.NASDAQ: TENX
EPS (Diluted) · Q1 FY2026 · quarter ended Mar 2026
EPS (Diluted) remains negative
Q1 FY2026 EPS (Diluted) was -$0.35, compared with -$0.28 a year earlier. Trailing-twelve-month EPS (Diluted) was -$1.41.
Context
- EPS (Diluted) grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 4 analysts of -$1.95 (-45.3%) for the fiscal year ending Dec 2026, a slowdown from the -16.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$0.35+10.3% QoQ
- Last fiscal yearDec 2025
- -$1.34-16.5% YoY
- LTMMar 2026
- -$1.41+43.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -25.0% | -45.7% | -20.7 pp |
| 1 year | -16.5% | -45.3% | -28.8 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
USD · from the income statement
- Latest · FY2025
- (1.34) USD
- Year-over-year change
- -16.5%
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.34) | -16.5% |
| FY2024 | 2024-12-31 | (1.15) | +96.3% |
| FY2023 | 2023-12-31 | (31.04) | +94.8% |
| FY2022 | 2022-12-31 | (600.80) | +76.2% |
| FY2021 | 2021-12-31 | (2,524.80) | — |
EPS (Diluted) vs competitors
How TENX compares with its peers on the latest reported figures
- TENX's LTM Mar 2026 EPS (Diluted) of -$1.41 is the 4th highest of the 7 companies compared; the peer median is -$1.33.
- Its year-over-year change of +43.1% is the 4th highest of 7, against a peer median of +52.8%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $2.66 | +153.8% | — | |
| LTM Jun 2026 | -$0.86 | +78.5% | — | |
| LTM Mar 2026 | -$1.1 | +27.2% | — | |
| LTM Mar 2026 | -$1.41 | +43.1% | — | |
| LTM Mar 2026 | -$1.56 | +87.0% | — | |
| LTM Mar 2026 | -$2.5 | +18.3% | — | |
| LTM Jun 2026 | -$28.87 | -2050.7% | — | |
| Peer median (excluding TENX) | -$1.33 | +52.8% | — | |
Competitors are the stored peer set for TENX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 25.15M | 5.38M | 3.23M | 12.71M | 32.67M |
| Selling, General & Admin | 7.58M | 5.68M | 5.01M | 6.79M | 23.71M |
| Operating Expenses | 32.73M | 11.05M | 8.23M | 19.49M | 56.39M |
| Depreciation & Amortization | 108.98K | 113.33K | 8K | 0 | 0 |
| EBITDA | (32.36M) | (10.93M) | (7.68M) | (17.58M) | (52.6M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (32.73M) | (11.05M) | (8.23M) | (19.49M) | (56.39M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 1.91M | 3.82M |
| Interest Expense | 949 | 4.44K | 23.97K | 23K | 0 |
| Other Income / Expenses | 253.88K | 4.75K | 523K | 1.89M | 3.79M |
| Income Before Tax | (32.47M) | (11.05M) | (7.71M) | (17.6M) | (52.6M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (32.47M) | (11.05M) | (7.71M) | (17.6M) | (52.6M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2,524.80) | (600.80) | (31.09) | (1.15) | (1.34) |
| EPS (Diluted) | (2,524.80) | (600.80) | (31.04) | (1.15) | (1.34) |
| Weighted Avg Shares | 12.86K | 18.39K | 248K | 15.27M | 39.22M |
| Weighted Avg Shares (Diluted) | 12.86K | 18.39K | 248.45K | 15.27M | 39.22M |
Tenax Therapeutics, Inc.
NASDAQ:TENX
Intrinsic Alpha fair value
Locked
Current Price
$1.91
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.